Skip to content

Aura Biosciences, Inc. AURA Investing Cash Flow

Investing Cash Flow at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
-$1.04B-250%
Merck & Co. logo
Merck & Co.MRK
-$10.21B-587%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
-$31.65M-867%
UroGen Pharma logo
UroGen PharmaURGN
-$20.69M+20.3%
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
$118.95M+49.0%
CG Oncology logo
CG OncologyCGON
-$334.85M-79.3%

Other financials

Income statement

See full
Operating income-$34.9M-20.1%
Net income-$33.7M-22.6%
EPS (diluted)-$0.50+9.1%

Balance sheet

See full
Cash & equivalents$84.8M+122%
Total debt$17.0M-7.9%
Total equity$107.2M-16.2%
Total assets$137.7M-11.4%

Cash flow

See full
Operating cash flow-$29.9M-28.0%
CapEx$102.0K-45.5%
Free cash flow-$30.0M-27.4%

Valuation

See full
Market cap$709.23M+89.4%
Enterprise value$641.43M+80.8%

Returns & leverage

See full
Return on equity-95.6%+222pp
Debt / equity0.2×0.0×
Current ratio7.1×-4.0×

Where this comes from

Reported directly by Aura Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The official record: Aura Biosciences, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Aura Biosciences, Inc.'s investing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Aura Biosciences, Inc.'s investing cash flow?
Aura Biosciences, Inc. (AURA) reported investing cash flow of $54.9M in Q1 2026.
How has Aura Biosciences, Inc.'s investing cash flow changed year-over-year?
Aura Biosciences, Inc.'s investing cash flow increased by 84.1% year-over-year, from $29.81M to $54.9M.
What does investing cash flow mean?
Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.